Patient Centric Needle-Free Therapies Will Capture Global Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
09 Aug 25
Updated
21 Aug 25
AnalystHighTarget's Fair Value
US$14.30
73.0% undervalued intrinsic discount21 Aug
US$3.86
1Y
-13.3%7D
-7.7%1Y
-13.3%7D
-7.7%